Chemotherapy and allo-HSCT for young patients with aggressive ATL.

Autor: Fuji S; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan. Electronic address: fujishige1231@gmail.com.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2024 Dec; Vol. 147, pp. 107596. Date of Electronic Publication: 2024 Sep 27.
DOI: 10.1016/j.leukres.2024.107596
Abstrakt: Adult T-cell leukemia-lymphoma (ATL) is an aggressive malignancy with a poor prognosis, especially for patients with the aggressive subtype. While conventional chemotherapy offers short-term disease control, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most promising curative approach for young, transplant-eligible patients. This review focuses on current treatment strategies for aggressive ATL in this specific population. We discuss the rationale for early upfront allo-HSCT following induction chemotherapy. The advent of allo-HSCT using alternative donors, particularly haploidentical HCT, has broadened the applicability of early upfront allo-HSCT in patients with aggressive ATL worldwide. Finally, we address emerging therapies that may improve outcomes in the context of allo-HSCT, paving the way for further advancements in the treatment of aggressive ATL.
Competing Interests: Declaration of Competing Interest There is no conflict of interest to declare.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: